- Home
- OCG vs PPCB Comparison
OCG vs PPCB Comparison
Compare OCG & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OCG | PPCB |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Hong Kong | Australia |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.2M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | OCG | PPCB |
|---|---|---|
| Price | $0.67 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 450.5K | ★ 739.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.16 |
| 52 Week High | $19.29 | $10.69 |
Technical Indicators
Market Signals| Indicator | OCG | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 30.64 |
| Support Level | $0.04 | $0.16 |
| Resistance Level | $4.24 | $0.40 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 11.14 | 12.02 |
Price Performance
Historical ComparisonAbout OCG Oriental Culture Holding LTD
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.